Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from those highs to 12-year lows at $137.33. The medical sector biotechnology ...

Deep-pocketed investors have adopted a bullish approach towards Biogen (NASDAQ:BIIB), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

Below is Validea's guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Earnings Yield Investor model based on the published strategy of ...

In early trading on Wednesday, shares of Gilead Sciences topped the list of the day's best performing components of the Nasdaq 100 index, trading up 8.0%. Year to date, Gilead Sciences registers a ...

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the April 4th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...

Investors with a lot of money to spend have taken a bullish stance on Biogen (NASDAQ:BIIB). And retail traders should know. We noticed this today when the trades showed up on publicly available ...

Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Biogen Inc (Symbol: BIIB), where a total volume of 11,054 contracts has been traded ...

Biogen Inc. (BIIB) came out with quarterly earnings of $3.44 per share, beating the Zacks Consensus Estimate of $3.42 per share. This compares to earnings of $2.95 per share a year ago.

Biogen Inc. (BIIB) is expected to deliver a year-over ... estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top ...

BIOGEN ($BIIB) posted quarterly earnings results on Wednesday, February 12th. The company reported earnings of $3.44 per share, beating estimates of $3.42 by $0.02 ...

led to a 4.3% drop in Biogen's stock price following the announcement. For the current fiscal year, ending in December, analysts expect BIIB’s EPS to plunge 3.9% to $15.83 on a diluted basis.